Biocon Biologics

The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study

Biocon Biologics enters US market with YESINTEK, offering treatment options for Crohn’s disease, ulcerative colitis, plaque…

Biocon’s subsidiary Biocon Biologics, which also participated independently in the assessment for the first time, reported an…

The VAI classification was given to Biocon Biologics’ Insulins facilities in Johor Bahru, Malaysia

The company transformed from a two-country operation focused on Development and Manufacturing, to a fully integrated company

Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth

YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children

The biosimilar Ustekinumab-kfce is set for commercialisation in the US by February 2025 under a licensing agreement with Janssen

The shortage of qualified healthcare professionals, coupled with the rising prevalence of diabetes, creates a critical health…

Over 50,000 global industry professionals, including key decision-makers, gathered at the event to explore new partnerships and…